Herpes vector-mediated expression of proenkephalin reduces bone cancer pain.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12402268.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We examined whether a herpes simplex virus vector that expresses human proenkephalin could be used to attenuate nociception in a model of bone cancer pain in mice. Osteolytic sarcoma cells were implanted into the medullary space of the right femur, followed by a subcutaneous inoculation of a replication-defective herpes simplex virus vector expressing human proenkephalin (vector SHPE) or a lacZ-expressing control vector (vector SHZ). SHPE-inoculated mice demonstrated a significant, naltrexone-reversible decrease in pain-related behavior assessed during open-field motor activity. These results suggest that gene transfer with an enkephalin-expressing vector may be used to treat pain resulting from cancer in bone.
Medical subject headings
- Bone Neoplasms
- Enkephalins
- Genetic Therapy
- Genetic Vectors
- Osteosarcoma
- Palliative Care
- Protein Precursors
- Simplexvirus